Present and prospect of transarterial chemoembolization combined with tyrosine kinase inhibitor and PD-1 inhibitor for unresectable hepatocellular carcinoma  

作　　者：Rui Zhang Yan-Hui Liu Yu Li Nan-Nan Li Zheng Li 

机构地区：[1]Department of Pharmacy,The Second People’s Hospital of Hefei,Hefei Hospital Affiliated to Anhui Medical University,Hefei 230011,Anhui Province,China [2]Department of Clinical Pharmacy,Anhui Provincial Children’s Hospital,Hefei 230000,Anhui Province,China [3]Department of Pharmacy,Taihe County People’s Hospital of Anhui Province,Fuyang 236600,Anhui Province,China [4]University of Science and Technology of China,The First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,Anhui Province,China [5]Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells,College of Health Sciences,School of Life Sciences,Jiangsu Normal University,Xuzhou 221000,Jiangsu Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2024年第11期4315-4320,共6页世界胃肠肿瘤学杂志（英文）

基　　金：The National Natural Science Foundation of China,No.82104525;The Natural Science Foundation of the Jiangsu Higher Education Institutions of China,No.21KJB360009.

摘　　要：In this editorial,we comment on the article(World J Gastrointest Oncol 2024;16:1236-1247),which is a retrospective study of transarterial chemoembolization(TACE)combined with multi-targeted tyrosine kinase inhibitor(TKI)and programmed cell death protein-1(PD-1)inhibitor for the treatment of unresectable hepatocellular carcinoma(HCC).Herein,we focus specifically on the mechanisms of this triple therapy,administration sequence and selection of each medication,and implications for future clinical trials.Based on the interaction mechanisms between medications,the triple therapy of TACE+TKI+PD-1 is proposed to complement the deficiency of each monotherapy,and achieve synergistic antitumor effects.Although this triple therapy has been evaluated by several retrospective trials,it is still controversial whether the triple therapy achieves better clinical benefits,due to the flawed study design and heterogeneity in medications.In addition,the administration sequence,which may greatly affect the clinical benefit,needs to be fully considered at clinical decision-making for obtaining better prognosis.We hope that this editorial could contribute to the design and optimization of future trials.

关 键 词：Transarterial chemoembolization Multi-targeted tyrosine kinase inhibitor Programmed cell death protein-1 inhibitor Unresectable hepatocellular carcinoma Mechanism 

分 类 号：R735.7[医药卫生—肿瘤]